Treatment of Psoriasis: A Survey on Patient Preference and Satisfaction

L Green; A Armstrong; CF Teller; S Bell; T Lin

L Green

George Washington University School of Medicine, Washington, DC

A Armstrong

Keck School of Medicine, University of Southern California, Los Angeles, CA

CF Teller

Bellaire Dermatology Associates, Houston, TX

S Bell

National Psoriasis Foundation

T Lin

Ortho Dermatologics*, Bridgewater, NJ *Ortho Dermatologics is a division of Bausch Health US, LLC.

Keywords

Psoriasis, Survey, Satisfaction

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496-509.
2. Visconti, et al. J Comp Eff Res. 2019;8(12):947-949.
3. Menter, et al. J Am Acad Dermatol. 2009;60(4):643-659.

Poster PDF

Published

Jan 28, 2020

How to Cite

Green, L., Armstrong, A., Teller, C., Bell, S., & Lin, T. (2020). Treatment of Psoriasis: A Survey on Patient Preference and Satisfaction. SKIN The Journal of Cutaneous Medicine, 4(1), S1. Retrieved from https://jofskin.org/index.php/skin/article/view/827

Issue

Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

Section

Poster Presentations at 2020 Winter Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich, Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
N Bhatia, W Werschler, H Baldwin, J Sugarman, L Stein Gold, L Green, E Lain, Long-Term Efficacy and Safety of Benzoyl Peroxide Cream, 5%, Prepared with Microencapsulation in Papulopustular Rosacea: Results from an Extension of Two Phase 3, Vehicle-Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
E Guttman-Yassky, A Blauvelt, L Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson, Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
C Leonardi, K Fahrbach, B Neupane, A Armstrong , K Gordon, S Kiri, V Taieb, L McClung, Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
E Guttman-Yassky, A Blauvelt, L.F. Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson, Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
A Blauvelt, A Armstrong, P Rich, R Kisa, A Guana, X Meng, K Callis Duffin, Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
A Moore, L Green, S Bruce, N Sadick, E Tschen, P Werschler, S Dhawan, D Forsha, M Gold, S Guenthner, S Kempers, L Kircik, J Parish, M Rendon, P Rich, L Stein-Gold, S Tyring, R Weiss, A Nasir, C Schmitz, T Boodhoo, A Kaoukhov, D Berk, F Cook-Bolden, Ayman Grada, Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
G Martin, B Berman, S Feldman, A Armstrong , M Edwards, S Graziadio, R McCool, M Arber, E Carr, D James, M Chapman-Rounds, E Fumero, M Schuchardt, A Grada, Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Z Draelos, F Cook-Bolden, L Green, E Guenin, G Martin, R Pillai, Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

1 2 3 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)